DAWES KAREN A 4
4 · REPLIGEN CORP · Filed Jun 14, 2024
Insider Transaction Report
Form 4
REPLIGEN CORPRGEN
DAWES KAREN A
Director
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2024-06-14+2,953→ 0 totalExercise: $67.71Exp: 2029-05-15→ Common Stock (2,953 underlying) - Exercise/Conversion
Common Stock
2024-06-14$67.71/sh+2,953$199,948→ 88,170 total
Footnotes (1)
- [F1]This option is fully vested and exercisable.